Etihad Cargo and EFL Global successfully deliver vital antiretroviral drugs to Brazil

More than 55,000kg carried on single Boeing 777 through Abu Dhabi

  
Etihad Cargo and EFL Global successfully deliver vital antiretroviral drugs to Brazil

Abu Dhabi, United Arab Emirates– Etihad Cargo, the cargo and logistics arm of Abu Dhabi’s Etihad Aviation Group, and global supply chain company EFL Global, have successfully carried a vital consignment of antiretroviral drugs from India to Brazil.

The shipment, which weighed more than 55,000kg, was transported on behalf of a leading manufacturer head quartered in Hyderabad and delivered to São-Paulo-Guarulhos International Airport in Brazil.

“The sheer size of the consignment and the need for stringent product integrity over such a long distance had seen other carriers turn down the shipment. Utilising Etihad Cargo’s pharmaceutical logistics capabilities and EFL’s extensive industry expertise, the shipment was successfully delivered, maintaining strict controls across the entire journey,” explained Martin Drew, Senior Vice President Sales and Cargo, Etihad Aviation Group. “The cargo was carried from origin to destination in the same flight, with no vessel change in order to preserve the consignment’s condition.”

Etihad Cargo leveraged its IATA CEIV certification for pharmaceutical logistics and capability to facilitate temperature-sensitive cargo shipments between +25⁰C and -80⁰C, and EFL’s CEIV and GDP compliance.

Maintaining the shipment’s integrity, EFL handed the consignment to Etihad Cargo in Hyderabad, with the UAE’s national carrier transiting the shipment through Abu Dhabi International Airport and Milan’s Malpensa International Airport en-route to São Paulo. Etihad Cargo and EFL collaborated to ensure data tracking and real-time status monitoring throughout the journey.

“Customers trust our capability to move lifesaving medications across continents in the best way possible. And we take this responsibility very seriously,” explained Rooso Ramachandran, Chief Commercial Officer of EFL Global – India. “Being a global supply chain service provider, we are heavily invested in having the right partnerships and compliance in place to uphold our promise. Each step of the operation is stringently planned with the best possible resources that ensure a seamless delivery, regardless of the complexities.”

In the past year, Etihad Cargo has increased pharmaceutical shipments by 50 per cent via its industry leading PharmaLife product. In addition to supporting global customers, the IATA CEIV-certified product has facilitated Etihad Cargo’s support of Abu Dhabi’s HOPE Consortium’s efforts to serve global demand for COVID-19 vaccines.

Etihad Cargo currently operates across more than 1,050 IATA CEIV Pharma/GDP certified trade lanes which ensure the integrity of products during transportation. Driven largely from a demand for both CRT (+15 to +25°C) and COL (+2 to +8°C) segments, Etihad Cargo has also received strong growth for ERT (+2 to +25°C) shipments, launched at the end of last year. 

“Etihad Cargo now has industry-leading expertise in the global transportation of temperature controlled and time-sensitive pharmaceutical products, including vaccines, operating to stringent manufacturers' requirements,” explained Drew. “The IATA CEIV certification has reaffirmed Etihad Cargo’s strength in this sector and boosted partner trust to deliver a quality product solution across 54 pharma stations with dedicated experts available for advice.”

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.


More From Press Releases